A Multicenter Randomized Cross-Over Study Evaluating the Efficacy and Safety of Silodosin in Adult Women With Voiding Dysfunction
Background Voiding dysfunction in adult women is a clinically significant condition associated with impaired quality of life and limited evidence-based pharmacological treatment options. Selective α1A-adrenergic antagonists such as silodosin may reduce urethral resistance and improve voiding efficiency; however, robust randomized data in women remain limited. This study addresses the need for high-quality evidence in this population.
Objectives To evaluate the efficacy and safety of silodosin compared to placebo in adult women with voiding dysfunction using a randomized cross-over study design.
Methods This is a prospective, multicenter, randomized, placebo-controlled cross-over study conducted at Ministry of Health hospitals in Kuwait. Adult women aged 21 years and older with clinically diagnosed voiding dysfunction will be enrolled. Participants will receive silodosin and placebo in a randomized sequence, separated by a washout period. Each participant will serve as her own control.
Expected Results / Conclusions The study is expected to clarify the role of silodosin in improving voiding symptoms in adult women and to provide safety data to guide future clinical practice.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Background:
Female voiding dysfunction and non-neurogenic lower urinary tract symptoms (LUTS) represent a common yet under-recognized clinical problem that significantly impacts quality of life. Symptoms may include hesitancy, straining, weak urinary stream, prolonged voiding time, and a sensation of incomplete bladder emptying. Despite their prevalence, diagnostic pathways and management strategies in women remain heterogeneous and less well standardized compared to male populations. Current international guidance highlights the complexity of female LUTS and emphasizes the need for better characterization and evidence-based treatment strategies, particularly for voiding-predominant symptoms and functional bladder outlet obstruction [1].
The European Association of Urology (EAU) guidelines on female non-neurogenic LUTS underscore that female voiding dysfunction is multifactorial and often underdiagnosed, with limited high-quality evidence guiding pharmacological management [1]. Similarly, contemporary reviews and International Continence Society (ICS) discussions have highlighted substantial gaps in clinical trials addressing female voiding dysfunction, particularly interventional studies evaluating medical therapies targeting urethral and bladder outlet mechanisms [2,3].
Alpha-adrenergic receptors, particularly the α1A subtype, play an important role in urethral smooth muscle tone. Pharmacological blockade of these receptors has a well-established role in male lower urinary tract symptoms. In women, emerging evidence suggests that alpha-blockers may reduce functional urethral resistance and improve voiding efficiency; however, available data remain limited and heterogeneous. A systematic review and meta-analysis evaluating alpha-blocker use in women with LUTS demonstrated potential symptom improvement but emphasized variability in study design, patient selection, and outcome measures, reinforcing the need for well-designed randomized trials [4]. Additional systematic reviews have similarly reported modest benefits of alpha-blockers in selected female populations, while calling for higher-quality evidence to guide routine clinical use [5].
Non-neurogenic female bladder outlet obstruction and voiding dysfunction remain challenging clinical entities, with recent reviews highlighting the lack of standardized therapeutic pathways and the reliance on extrapolated evidence from male studies [6]. These reviews consistently identify selective alpha-blockade as a promising but insufficiently studied therapeutic option, particularly in women without overt anatomical obstruction.
Silodosin is a highly selective α1A-adrenergic receptor antagonist with a favorable pharmacological profile and established safety record. Recent prospective studies have explored the use of silodosin in women with lower urinary tract and voiding symptoms, suggesting potential improvements in symptom scores and voiding parameters, with acceptable tolerability [7]. Additional studies evaluating silodosin, either alone or in combination with other agents, have further supported its potential role in female LUTS management, though these studies remain limited by sample size, study design, or focus on storage-predominant symptoms [8]. Emerging abstracts and presentations at international continence meetings have continued to highlight growing clinical interest in silodosin for female voiding dysfunction, while reinforcing the need for rigorous randomized controlled trials [7-11].
Given the persistent evidence gaps, the absence of standardized pharmacological treatment for female voiding dysfunction, and the promising yet inconclusive data surrounding selective alpha-blockade, there is a clear need for a well-designed randomized clinical study. A randomized cross-over, placebo-controlled design allows each participant to serve as her own control, minimizing inter-individual variability and reducing unnecessary drug exposure. This approach is particularly well suited for functional voiding disorders and aligns with ethical principles of participant safety and scientific rigor.
This multicenter randomized cross-over study aims to address these gaps by evaluating the efficacy and safety of silodosin in adult women with voiding dysfunction, thereby contributing robust evidence to inform clinical practice and future guideline development.
Aim & Objectives:
Aim: To assess the efficacy and safety of silodosin in adult women with voiding dysfunction.
Objectives:
- To compare voiding symptoms during silodosin and placebo treatment periods
- To assess patient-reported symptom improvement
- To evaluate the safety and tolerability of silodosin
- To compare outcomes between treatment sequences
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Said M Yaiesh, BMBCh MSurg MSurgEd KBU
- Telefonnummer: +96597964200
- E-post: syaiesh@hotmail.com
Studer Kontakt Backup
- Navn: Tariq F Al-Shaiji, BMBCh FRCSC
- Telefonnummer: +96599773789
- E-post: tshaiji@gmail.com
Studiesteder
-
-
Kuwait
-
Kuwait City, Kuwait, Kuwait, 00000
- Amiri Hospital
-
Ta kontakt med:
- Abdullatif E Alterki, MD FRCSC
- Telefonnummer: +96522450005
- E-post: alterki1@gmail.com
-
Ta kontakt med:
- Rehan Khan, MD
- Telefonnummer: +96522450005
- E-post: doc.rnk@gmail.com
-
Hovedetterforsker:
- Meshari F Almutairi, BMBCh KBU
-
Kuwait City, Kuwait, Kuwait, 00000
- Farwaniya Hospital
-
Ta kontakt med:
- Faisal M Alhajeri, BMBCh FEBU
- Telefonnummer: +96524888000
- E-post: falhajry75@gmail.com
-
Ta kontakt med:
- Feras T Ajrawi, BMBCh KBU
- Telefonnummer: +96524888000
- E-post: ferasalajrawi@hotmail.com
-
Hovedetterforsker:
- Awad Thahir, MD KBU
-
Kuwait City, Kuwait, Kuwait, 00000
- Jaber Al Ahmad Al Jaber Al Sobah Hospital
-
Ta kontakt med:
- Sulaiman M Almazeedi, BMBCh KBGS
- Telefonnummer: +9652530500
- E-post: jaber.hospital@moh.gov.kh
-
Ta kontakt med:
- Ali Lairi
- Telefonnummer: +9652530500
- E-post: jaber.hospital@moh.gov.kh
-
Hovedetterforsker:
- Said M Yaiesh, BMBCh
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
Eligible participants must have clinically significant voiding symptoms including one or more of the following:
- Difficulty initiating voiding
- Slow urinary stream
- Intermittent urinary stream
- Straining to void
- Sensation of incomplete bladder emptying
AND at least one objective parameter suggestive of impaired bladder emptying:
- Post-void residual urine volume ≥100 mL
- Maximum urinary flow rate (Qmax) <15 mL/sec with voided volume >150 mL
- Abnormal pressure-flow findings where available"
Exclusion Criteria:
- Pregnancy or breastfeeding
- Active urinary tract infection
- Neurogenic bladder dysfunction
- Significant pelvic organ prolapse requiring intervention
- Previous bladder outlet or urethral surgery
- Severe renal or hepatic impairment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Silodosin → Placebo
Participants will receive silodosin 8 mg orally once daily for 8 weeks, followed by a 2-week washout period, then matching placebo once daily for 8 weeks.
|
Silodosin 8 mg oral capsule administered once daily for 8 weeks.
In the crossover design, participants will receive silodosin during one treatment period and matching placebo during the alternate treatment period, separated by a 2-week washout period.
Matching placebo oral capsule administered once daily for 8 weeks.
The placebo will be identical in appearance and packaging to silodosin to maintain masking.
Participants will receive placebo during one treatment period and silodosin during the alternate treatment period, separated by a 2-week washout period.
|
|
Eksperimentell: Placebo → Silodosin
Participants will receive matching placebo orally once daily for 8 weeks, followed by a 2-week washout period, then silodosin 8 mg orally once daily for 8 weeks.
|
Silodosin 8 mg oral capsule administered once daily for 8 weeks.
In the crossover design, participants will receive silodosin during one treatment period and matching placebo during the alternate treatment period, separated by a 2-week washout period.
Matching placebo oral capsule administered once daily for 8 weeks.
The placebo will be identical in appearance and packaging to silodosin to maintain masking.
Participants will receive placebo during one treatment period and silodosin during the alternate treatment period, separated by a 2-week washout period.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Total International Prostate Symptom Score (IPSS) Following Treatment
Tidsramme: Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
Change in total International Prostate Symptom Score (IPSS) from the beginning to the end of each 8-week treatment period.
The IPSS consists of 7 symptom questions, each scored from 0 to 5, giving a total score ranging from 0 to 35, with higher scores indicating more severe lower urinary tract symptoms.
The treatment effect of silodosin will be compared with that of placebo within the crossover design.
|
Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in IPSS Voiding Subscore
Tidsramme: Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
Change in the International Prostate Symptom Score (IPSS) voiding subscore from the beginning to the end of each 8-week treatment period.
The voiding subscore comprises the IPSS items relating to incomplete emptying, intermittency, weak stream, and straining; higher scores indicate greater symptom severity.
|
Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
|
Change in Overactive Bladder Symptom Score (OABSS)
Tidsramme: Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
Change in total OABSS from the beginning to the end of each 8-week treatment period.
Higher scores indicate greater overactive bladder symptom severity.
|
Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
|
Change in Quality-of-Life Score
Tidsramme: Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
Change in the IPSS quality-of-life score from the beginning to the end of each 8-week treatment period.
The score ranges from 0 (delighted) to 6 (terrible), with higher scores indicating worse urinary symptom-related quality of life.
|
Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
|
Change in Post-Void Residual Urine Volume
Tidsramme: Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
Change in post-void residual urine volume, measured in milliliters, from the beginning to the end of each treatment period.
|
Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
|
Change in Maximum Urinary Flow Rate (Qmax)
Tidsramme: Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
Change in maximum urinary flow rate, measured by uroflowmetry in mL/second, from the beginning to the end of each treatment period.
|
Beginning and end of each 8-week treatment period (Weeks 0-8 and Weeks 10-18).
|
|
Adverse Events
Tidsramme: Throughout each treatment period and through completion of the 18-week study.
|
Incidence and nature of adverse events occurring during treatment with silodosin and placebo, including assessment of severity and relationship to study treatment.
|
Throughout each treatment period and through completion of the 18-week study.
|
|
Patient Global Impression of Improvement (PGI-I)
Tidsramme: End of each 8-week treatment period (Weeks 8 and 18).
|
Patient-reported overall improvement in urinary symptoms assessed using the Patient Global Impression of Improvement (PGI-I) scale at the end of each treatment period.
The PGI-I is a 7-point scale ranging from 1 (very much better) to 7 (very much worse), with lower scores indicating greater perceived improvement.
|
End of each 8-week treatment period (Weeks 8 and 18).
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Tariq F Al-Shaiji, BMBCh FRCSC, Jaber Al Ahmad Hospital
- Hovedetterforsker: Said M Yaiesh, BMBCh MSurg MSurgEd KBU, Jaber Al Ahmad Hospital
- Hovedetterforsker: Meshari F Almutairi, BMBCh KBU, Amiri Hospital
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Alenezi A, Salem S, Taleb S, Almazeedi A, Alfahad M, Alkabbani M, Alyousef R, Al-Terki A, Al-Shaiji T. Silodosin in Females with Voiding Dysfunction: Safety and Efficacy, A Pilot Study. International Continence Society Annual Congress 2023; Abstract 382.
- Sinha S, Yang CC, Arlandis S, Goldman HB. Female voiding dysfunction: A review of clinical presentation, urodynamic diagnosis and management. Continence. 2023;6:100578. doi:10.1016/j.cont.2023.100578
- Jeon BJ, Chang HK, Tae BS, Park JY, Yoon DK, Bae JH. Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder. Int Neurourol J. 2024 Dec;28(4):264-269. doi: 10.5213/inj.2448374.187. Epub 2024 Dec 31.
- Sinha A, Tuttle B, Weidner A. Non-neurogenic Voiding Dysfunction in Pediatric Patients and Female Adults: Review of Current Clinical Trials. Obstet Gynecol Surv. 2026 Jan 1;81(1):29-38. doi: 10.1097/OGX.0000000000001467. Epub 2026 Jan 19.
- Arlandis S, Bo K, Cobussen-Boekhorst H, Costantini E, de Heide M, Farag F, Groen J, Karavitakis M, Lapitan MC, Manso M, Arteaga SM, Nambiar AK, Riogh ANA, O'Connor E, Omar MI, Peyronnet B, Phe V, Sakalis VI, Sihra N, Tzelves L, van Poelgeest-Pomfret ML, van den Bos TWL, van der Vaart H, Harding CK. European Association of Urology Guidelines on the Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 2: Underactive Bladder, Bladder Outlet Obstruction, and Nocturia. Eur Urol. 2022 Jul;82(1):60-70. doi: 10.1016/j.eururo.2022.01.044. Epub 2022 Feb 16.
- Perrin A, Corcos J. Nonneurogenic female bladder outlet obstruction: Conservative and medical management. Neurourol Urodyn. 2025 Jan;44(1):37-43. doi: 10.1002/nau.25318. Epub 2023 Nov 6.
- Kang TW, Kim SJ, Chang KD, Kim MH, Chung HC. Effect of the symptom-based alpha-blocker treatment on lower urinary tract symptoms in women: systematic review and meta-analysis. Ther Adv Urol. 2021 Oct 26;13:17562872211053679. doi: 10.1177/17562872211053679. eCollection 2021 Jan-Dec.
- Wee CB, Kim TH, Tae JH, Choi SY. Efficacy and Safety of Silodosin for the Treatment of Female LUTS: A 12-Week Prospective, Single-Center Study. Low Urin Tract Symptoms. 2025 Jan;17(1):e70005. doi: 10.1111/luts.70005.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2026/3235
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .